Marshall Wace’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.01M Buy
239,881
+110,533
+85% +$2.8M 0.01% 1242
2026
Q2
$3.28M Buy
+129,348
New +$3.06M ﹤0.01% 1588
2025
Q3
– Sell
-190,366
Closed -$4.55M – 3278
2025
Q2
$4.55M Buy
+190,366
New +$4.8M 0.01% 1187
2025
Q1
– Sell
-42,613
Closed -$803K – 2976
2024
Q4
$803K Sell
42,613
-482,336
-92% -$8.47M ﹤0.01% 1832
2024
Q3
$7.9M Sell
524,949
-446,194
-46% -$7.63M 0.01% 845
2024
Q2
$27.8M Buy
971,143
+159,791
+20% +$4.55M 0.04% 401
2024
Q1
$23.7M Buy
811,352
+331,159
+69% +$10.2M 0.04% 458
2023
Q4
$16.2M Sell
480,193
-5,452
-1% -$160K 0.03% 539
2023
Q3
$14.9M Buy
485,645
+97,348
+25% +$3.51M 0.03% 516
2023
Q2
$15.6M Buy
388,297
+69,136
+22% +$2.86M 0.03% 572
2023
Q1
$13M Buy
319,161
+193,804
+155% +$7.71M 0.03% 615
2022
Q4
$4.84M Buy
125,357
+82,396
+192% +$4.01M 0.01% 1207
2022
Q3
$2.29M Buy
42,961
+24,638
+134% +$1.37M 0.01% 1918
2022
Q2
$1.07M Buy
+18,323
New +$1.2M ﹤0.01% 2405
2022
Q1
– Sell
-205,322
Closed -$12.4M – 3854
2021
Q4
$12.4M Buy
205,322
+190,381
+1,274% +$10.5M 0.02% 721
2021
Q3
$837K Buy
+14,941
New +$861K ﹤0.01% 2124
2021
Q2
– Sell
-30,624
Closed -$2.15M – 2974
2021
Q1
$2.15M Buy
+30,624
New +$2.19M 0.01% 1292
2020
Q1
– Sell
-19,673
Closed -$891K – 1956
2019
Q4
$891K Sell
19,673
-253,489
-93% -$10.8M 0.01% 1014
2019
Q3
$10.4M Buy
+273,162
New +$10.9M 0.08% 282
2016
Q4
– Sell
-10,749
Closed -$368K – 1090
2016
Q3
$368K Buy
+10,749
New +$421K ﹤0.01% 835
2015
Q4
– Sell
-54,226
Closed -$2.23M – 1087
2015
Q3
$2.23M Buy
+54,226
New +$3.32M 0.03% 426

Other funds holding PCRX

Marshall Wace's PCRX Position: Q3 2026 in Review

Marshall Wace increased its Pacira BioSciences (PCRX) stake by 85% in Q3 2026, buying an estimated $2.8M and bringing the position to 239,881 shares worth $6.01M. The position accounts for 0.01% of the portfolio, ranked #1242.

Marshall Wace first reported a position in PCRX in Q3 2015 and has held it in 21 quarters since. The position peaked at $27.8M in Q2 2024. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Marshall Wace held 239,881 shares of Pacira BioSciences worth $6.01M as of Q3 2026.
  • Marshall Wace bought 110,533 Pacira BioSciences shares in Q3 2026, an estimated $2.8M.
  • Pacira BioSciences made up 0.01% of Marshall Wace's portfolio in Q3 2026, its #1242 holding.
  • Marshall Wace first reported a position in Pacira BioSciences in Q3 2015 and has held it in 21 quarters since.
  • Marshall Wace's Pacira BioSciences position peaked at $27.8M in Q2 2024.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.